Maharashtra FDA Revokes Cipla Pune Unit's Licence Over Drug Compliance Failures
What Happened
Maharashtra FDA cancelled the drug sale licences of Cipla's Pune C&F unit after finding lapses related to Reactin Plus tablets, including alleged misbranding, incomplete recall compliance, stock-record mismatches and improper storage practices. Stock worth about ₹11.19 lakh was also seized.
Key Takeaways
The crackdown highlights stricter regulatory scrutiny of pharmaceutical supply chains and compliance standards. The FDA said violations involving the storage, distribution, advertising, and recall of prescription medicines can invite stringent action due to their potential impact on drug safety and public health.